Método para la obtención de una línea celular tumoral resistente a vincristina
DOI:
https://doi.org/10.29105/qh1.2-79Keywords:
Vincristina, Tumoral, Glicoproteína PAbstract
Los mecanismos de resistencia a fármacos a nivel de membrana más comunes desarrollados por las células neoplásicas involucran la sobre-expresión de la glicoproteína P (gp-P), también llamada MDRP (del inglés Multi-Drug Resistance Protein). Su participación en el proceso de resistencia se manifiesta al disminuir la concentración terapéutica de un fármaco en el citoplasma al transportarlo al exterior apenas ingrese en la célula, impidiendo así que el fármaco sea efectivo. En base a lo anterior se implementó un método para la obtención de células de origen neoplásico resistentes a Vincristina, mediante exposición a dosis graduales, con el propósito de proveer un modelo celular útil para estudios moleculares, farmacéuticos o de citología.
Downloads
References
-[1] Dean M., Rzhetsky A., Allikmets R. 2001. The Human ATP-Binding Cassette (A BC) Transporter Superfamily. Genome Research 11( 7): 1156-1166. DOI: https://doi.org/10.1101/gr.GR-1649R
-[2] Sankatsing S., Beijnen J.H., Schinkel A.H., Lange J., Prins J.M. 2004. P Glycoprotein in Human Immunodeficiency Virus Type 1 lnfection and Therapy. Antimicrobial Agents and Chemotherapy 48( 4 ): 1073-1081. DOI: https://doi.org/10.1128/AAC.48.4.1073-1081.2004
-[3] Leonard G.D., Fojo T., Bates S.E. 2003. Toe Role of ABC Transporters in Clinical Practice. Cancer Biology. 8(5):411424. DOI: https://doi.org/10.1634/theoncologist.8-5-411
-[4] Borowski E., Bontemps-Gracz M.M., Piwkowska A. 2005. Strategies for overcoming ABC-transporters-mediated multidrug resistence (MDR) oftumor cells. Acta Biochimica Polonica. 52(3):609-627. DOI: https://doi.org/10.18388/abp.2005_3421
-[5] Miller J. 2000. Cancer Multidrug Resistance. Nature Biotechnology. Suplement. 18: 18-20. DOI: https://doi.org/10.1038/80051
-[6] Bontemps-Gracz M.M., Kupiecl A., Antonini I., Borowskil E. 2002. Toe ability to overcome multidrug resistance of tumor cell lines by novel acridine cytostatics with condensed heterocyclic rings. ActaBiochimica Polonica. 49(1 ):87-92. DOI: https://doi.org/10.18388/abp.2002_3824
-[7] Beck W.T., Cass C.E., Houghton P.J. 2000. Microtubule-targeting anticancer drugs derived from plants and microbes: Vinca alkaloids, taxanes and epothilones. En: Holland J.F., Frei E. III., Bast R.C. Jr., Kufe D.W., Morton D.L., Weichselbaum R.R. (e ds.) Cancer Medicine., 5a ed. Atlanta: American Cancer Society, p. 680-698.
Rivera-Fillat M.P., Pallarés-Trujillo J., Doménech C., Grau-Oliete M.R. 1988. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine. Br J Pharmacol. 93(4): 902-908. DOI: https://doi.org/10.1111/j.1476-5381.1988.tb11478.x
-[9] Noble R.L. 1990. The discovery of the vinca alkaloids-chemotherapeutic agents against cancer. Biochemistry and Cellular Biology. 68(12):1344-1351. DOI: https://doi.org/10.1139/o90-197
-[10] Bennouna J., Delord J.P. 2008. Campone M., Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clinical Cancer Research. 14(6):1625-1632. DOI: https://doi.org/10.1158/1078-0432.CCR-07-2219
-[11] Leveque D., Jehl F. 2007. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. Journal of Clinical Pharmacology. 47(5):579-588. DOI: https://doi.org/10.1177/0091270007299430
-[12] Simoens C., Vermorken J.B., Korst A.E., Pauwels B., De Pooter C.M., Pattyn G.G., Lambrechts H.A., Breillout F., Lardan F. 2006. Cell cycle effects ofvinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, invitro. Cancer Chemother Pharmacol. 58:210-218. DOI: https://doi.org/10.1007/s00280-005-0147-8
-[13] Lobert S., Fahy J., Hill B.T., Duflos A., Etievant C., Correia J.J. 2000. Vinca Alkaloid-Induced Tubulin Spiral Formation Correlates with Cytotoxicity in the Leukemic L 1210 Cell Line. Biochemistry. 39(39): 12053-12062. DOI: https://doi.org/10.1021/bi001038r
-[14] Ngan V.K., Bellman K., Hill B.T., Wilson L., Jordan M.A. 2001. Mechanism of Mitotic Block and Inhibition of Cell Proliferation by the Semisynthetic Vinca alkaloids Vinorelbine and its Newer Derivative Vinflunine. Molecular Pharmacology. 60(1) :225-232. DOI: https://doi.org/10.1124/mol.60.1.225
-[15] Jordan M.A., Thrower D., Wilson L. 1991. Mechanism ofinhibition by Vinca alkaloids. Cancer Res. 51 :2212-2222.
-[16] Lee W.P.,Lee C.L. 1994. Characterization of vincristine-resistant HOB 1 lymphoma cell line showing the classical MDR phenotype and altered expression of membrane glycoproteins. Oncology. 51 (1 ):2-8. DOI: https://doi.org/10.1159/000227300
-[17] Freshney R.I. 2005. Culture of Animal Cells: A Manual of Basic Technique. 5a. ed. Wiley-Liss, EEUU. p.p. 672. DOI: https://doi.org/10.1002/0471747599.cac006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2011 Alberto Gómez Treviño , Ma. Elena Cantú Cárdenas, Eduardo l. de la Rosa Moreno, Margarita Ortiz Martínez , Arturo S. Vázquez , Elena Mercadé Gill
This work is licensed under a Creative Commons Attribution 4.0 International License.
